Tenofovir (all routes except local)

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5134
R13375		 Floridia, 2018 Hypertension/preeclampsia during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: No Control group: Abacavir/Lamivudine-based Exposed group: TDF/emtricitabine-based Indication: HIV 0.46 [0.22;0.96] 16/661   13/252 29 661
ref
S5321
R13775		 Lin, 2018 Pregnancy hypertension 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 0.88 [0.02;45.17] C 0/59   0/52 0 59
ref
S5259
R13597		 Pan, 2016 Preeclampsia late pregnancy randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 0.34 [0.01;8.46] C 0/97   1/100 1 97
ref
S5127
R13310		 Ransom, 2013 Pre-eclampsia during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 1.15 [0.74;1.78] C 32/630   62/1,395 94 630
ref
Total 4 studies 0.77 [0.40;1.48] 124 1,447
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Floridia, 2018Floridia, 2018 0.46[0.22; 0.96]2966138%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Lin, 2018Lin, 2018 0.88[0.02; 45.17]0593%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pan, 2016Pan, 2016 0.34[0.01; 8.46]1974%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ransom, 2013Ransom, 2013 1.15[0.74; 1.78]9463055%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (4 studies) I2 = 37% 0.77[0.40; 1.48]1241,4470.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.76[0.31; 1.88]1231,29177%NAFloridia, 2018 Ransom, 2013 2 case control studiescase control studies 0 RCTRCT 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2 Type of controls unexposed, sickunexposed, sick 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2 exposed to other treatment, sickexposed to other treatment, sick 0.76[0.31; 1.88]1231,29177%NAFloridia, 2018 Ransom, 2013 2 Tags Adjustment   - No  - No 0.76[0.31; 1.88]1231,29177%NAFloridia, 2018 Ransom, 2013 2   - Randomisation  - Randomisation 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2 Control group   - Abacavir/Lamivudine-based  - Abacavir/Lamivudine-based 0.46[0.22; 0.96]29661 -NAFloridia, 2018 1   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 1.15[0.74; 1.78]94630 -NARansom, 2013 1   - Unexposed, sick  - Unexposed, sick 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 1.15[0.74; 1.78]94630 -NARansom, 2013 1   - TDF (only)  - TDF (only) 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2   - TDF/emtricitabine-based  - TDF/emtricitabine-based 0.46[0.22; 0.96]29661 -NAFloridia, 2018 1 Indication   - CHB  - CHB 0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2   - HIV  - HIV 0.76[0.31; 1.88]1231,29177%NAFloridia, 2018 Ransom, 2013 2 All studiesAll studies 0.77[0.40; 1.48]1241,44737%NAFloridia, 2018 Lin, 2018 Pan, 2016 Ransom, 2013 40.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.74.52.4110.000Floridia, 2018Lin, 2018Pan, 2016Ransom, 2013

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.50[0.04; 6.00]11560%NALin, 2018 Pan, 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.76[0.31; 1.88]1231,29177%NAFloridia, 2018 Ransom, 2013 20.510.01.0